Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

by | Dec 16, 2025 | Clinical Trials | 0 comments

​ Conditions: Phase 2; Zanzalintinib; Pembrolizumab; Advanced/Metastatic; Soft-Tissue Sarcoma

Interventions: Drug: Zanzalintinib; Drug: Pembrolizumab

Sponsors: M.D. Anderson Cancer Center; Exelixis

Not yet recruiting Conditions: Phase 2; Zanzalintinib; Pembrolizumab; Advanced/Metastatic; Soft-Tissue Sarcoma
Interventions: Drug: Zanzalintinib; Drug: Pembrolizumab
Sponsors: M.D. Anderson Cancer Center; Exelixis
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *